title: [Musculoskeletal disorders in HIV-infected patients.National AIDS Plan (PNS) and the AIDS Study Group (GESIDA)].
abstract: The aim of this paper is to present the most relevant musculoskeletal disorders, their diagnosis and treatment to the scientific community and the professionals in charge of patients with human immunodeficiency virus (HIV) infection. These recommendations have been agreed by a panel of experts from the National AIDS Plan (PNS) and the AIDS Study Group (GESIDA). The group have reviewed the efficacy and safety results of clinical trials, cohort studies and pharmacokinetic studies published in biomedical journals (PubMed and Embase), or presented at conferences. Three levels of evidence have been defined according to the sources of data: level A, randomized controlled trials; level B, cohort or case-control; and level C, descriptive studies and expert opinion. Based on this evidence, the authors have decided to recommend, consider or not recommend for each situation. The decrease in bone mineral density is common in HIV-infected patients on antiretroviral treatment, especially during the first year (from 2 to 4%), with a subsequent partial recovery. A dual energy x-ray absorptiometry (DEXA) scan is recommended in patients over 50 years old with HIV infection, history of bone fractures and/or risk factors. Treatment with bisphosphonates has been shown to be effective. Osteoarticular infections are more frequent than in the non-infected population. The level of immunosuppression, risk practice, and antiretroviral treatment should be considered for a proper diagnosis and therapeutic approach. Laboratory and imaging procedures recommended for the study of musculoskeletal processes in HIV infected subjects are the same as in the general population. Osteonecrosis and decreased bone mineral density are the most frequent alterations in children. An early diagnosis of bone disorders is needed. The influence of modifiable risk factors must be avoided and initiate treatment when necessary. Bisphosphonates have been effective in osteoporosis.
mesh_terms: D000328:Adult; D000367:Age Factors; D000465:Algorithms; D019380:Anti-HIV Agents / Q000009:adverse effects; D001168:Arthritis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D019317:Evidence-Based Medicine; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008403:Mass Screening; D009140:Musculoskeletal Diseases / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D010020:Osteonecrosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents